Literature DB >> 24362902

An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.

Jinlong Shi1, Hao Zuo, Lanchun Ni, Liang Xia, Longxiang Zhao, Mingjie Gong, Dekang Nie, Peipei Gong, Daming Cui, Wei Shi, Jian Chen.   

Abstract

The isocitrate dehydrogenase 1 (IDH1) gene mutation occurs frequently in glioma. While some studies have demonstrated that IDH1 mutations are associated with prolonged survival, the mechanism remains unclear. In this study, we found that growth was significantly inhibited in glioma cells overexpressing the mutated IDH1 gene. Furthermore, these cells were characterized by decreased intracellular NADPH levels accompanied by glutathione (GSH) depletion and reactive oxygen species (ROS) generation. Moreover, the increased apoptosis and the decreased proliferation were found in the glioma cells overexpressing the mutant IDH1 gene. Accordingly, our study demonstrates that using H2O2-regulated mutant IDH1 glioma cells could obviously increase the inhibition of cell growth; nevertheless, GSH had the opposite result. Our study provides direct evidence that mutation of IDH1 profoundly inhibits the growth of glioma cells, and we speculate that this is the major factor behind its association with prolonged survival in glioma. Finally, our study indicates that depletion of GSH and generation of ROS are the primary cellular events associated with this mutation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362902     DOI: 10.1007/s10072-013-1607-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

Review 1.  A redox cycle within the cell cycle: ring in the old with the new.

Authors:  S G Menon; P C Goswami
Journal:  Oncogene       Date:  2006-08-21       Impact factor: 9.867

Review 2.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

3.  Importance of glucose-6-phosphate dehydrogenase in the adaptive response to hydrogen peroxide in Saccharomyces cerevisiae.

Authors:  S Izawa; K Maeda; T Miki; J Mano; Y Inoue; A Kimura
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

4.  IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.

Authors:  Linda B C Bralten; Nanne K Kloosterhof; Rutger Balvers; Andrea Sacchetti; Lariesa Lapre; Martine Lamfers; Sieger Leenstra; Hugo de Jonge; Johan M Kros; Erwin E W Jansen; Eduard A Struys; Cornelis Jakobs; Gajja S Salomons; Sander H Diks; Maikel Peppelenbosch; Andreas Kremer; Casper C Hoogenraad; Peter A E Sillevis Smitt; Pim J French
Journal:  Ann Neurol       Date:  2011-03       Impact factor: 10.422

Review 5.  What made sesquiterpene lactones reach cancer clinical trials?

Authors:  Akram Ghantous; Hala Gali-Muhtasib; Heikki Vuorela; Najat A Saliba; Nadine Darwiche
Journal:  Drug Discov Today       Date:  2010-06-09       Impact factor: 7.851

6.  Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin.

Authors:  Jih I Chuang; Tsuey Y Chang; Hsiao S Liu
Journal:  Oncogene       Date:  2003-03-06       Impact factor: 9.867

7.  Kaempferol induces apoptosis in glioblastoma cells through oxidative stress.

Authors:  Vivek Sharma; Christy Joseph; Soumya Ghosh; Anindita Agarwal; Manoj Kumar Mishra; Ellora Sen
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

8.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

9.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

10.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

View more
  24 in total

1.  Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.

Authors:  Daniel R Wahl; Joseph Dresser; Kari Wilder-Romans; Joshua D Parsels; Shuang G Zhao; Mary Davis; Lili Zhao; Maureen Kachman; Stefanie Wernisch; Charles F Burant; Meredith A Morgan; Felix Y Feng; Corey Speers; Costas A Lyssiotis; Theodore S Lawrence
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

Review 2.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

3.  IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.

Authors:  Timucin Avsar; Tansu Bilge Kose; Muhammed Deniz Oksal; Gizem Turan; Turker Kilic
Journal:  Mol Biol Rep       Date:  2022-08-07       Impact factor: 2.742

4.  GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo.

Authors:  Tao Gong; Xia Zhang; Xinhong Wei; Shuhui Yuan; Muhammad G Saleh; Yulu Song; Richard A Edden; Guangbin Wang
Journal:  Neurochem Int       Date:  2020-10-22       Impact factor: 3.921

Review 5.  Metabolic regulation of innate and adaptive lymphocyte effector responses.

Authors:  Ann M Joseph; Laurel A Monticelli; Gregory F Sonnenberg
Journal:  Immunol Rev       Date:  2018-11       Impact factor: 12.988

6.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Authors:  Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti
Journal:  Nat Med       Date:  2015-01-19       Impact factor: 87.241

7.  Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.

Authors:  Jason K Wasserman; Garth Nicholas; Rebecca Yaworski; Anne-Marie Wasserman; John M Woulfe; Gerard H Jansen; Santanu Chakraborty; Thanh B Nguyen
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.

Authors:  Manabu Natsumeda; Hironaka Igarashi; Toshiharu Nomura; Ryosuke Ogura; Yoshihiro Tsukamoto; Tsutomu Kobayashi; Hiroshi Aoki; Kouichirou Okamoto; Akiyoshi Kakita; Hitoshi Takahashi; Tsutomu Nakada; Yukihiko Fujii
Journal:  Acta Neuropathol Commun       Date:  2014-11-07       Impact factor: 7.801

Review 9.  Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification.

Authors:  Alexandre Vallée; Yves Lecarpentier; Jean-Noël Vallée
Journal:  Biomedicines       Date:  2021-05-30

10.  IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.

Authors:  Xiao-Wei Wang; Marianne Labussière; Samuel Valable; Elodie A Pérès; Jean-Sébastien Guillamo; Myriam Bernaudin; Marc Sanson
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.